SecBot SecBot
8-K ·Filed Sep 9, 2026

INDP

Indaptus Therapeutics, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001493152-26-042037
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The $24M private placement provides a cash runway but at massive dilution cost, layered on top of a $100M ATM and a 58.9M-share S-3 resale registration. The company has no active pipeline and is pivoting to preclinical neurotechnology, a high-risk, early-stage pivot. Expect continued selling pressure as the ATM is utilized and the S-3 resale shares hit the market. Monitor for any Nasdaq compliance issues given the cumulative dilution.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$2.56
T+0 close · Sep 9, 2026 · via day close
Latest settled
−7.42%
T+20 · $2.37 · next T+60 in 17d
Vs SPY
−9.55%
α at T+20
Latest observation
+128.38%
T+47 · FF3 residual α
  1. T+0 · Sep 10 $2.56entry
  2. T+1 · 2mo ago +8.20%α +7.35% · $2.77
  3. T+5 · 2mo ago +53.52%α +52.89% · $3.93
  4. T+20 · 6w ago −7.42%α −9.55% · $2.37
  5. T+47 · todayOpen
  6. T+60 · in 17d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Indaptus Therapeutics entered into a stock purchase agreement for a $24M private placement of 20,338,974 shares, priced at Nasdaq Minimum Price plus $0.015. This capital raise follows a recently filed $100M ATM offering and an S-3 resale registration, creating a dual-track dilution scenario for a company with no active clinical programs and a going-concern risk. The massive dilution (15.3% of outstanding shares from this placement alone, plus the ATM overhang) is the dominant signal, overwhelming any positive from the cash infusion.

Key Financial Metrics

Offering Size
$24.0M
Dilution
15.3%

Key Facts

  • Indaptus entered a $24M private placement of 20,338,974 shares at Nasdaq Minimum Price + $0.015.
  • The company has 133,242,324 shares outstanding; this placement represents ~15.3% dilution.
  • Proceeds are for working capital, R&D, and early-stage research on a neurotechnology device for sleep conditions.
  • This filing follows a $100M ATM offering (filed Aug 31, 2026) and an S-3 resale registration for 58.9M shares (filed Aug 17, 2026).
  • The company has no active clinical programs, having discontinued its lead candidate Decoy20, and faces a going-concern risk.
  • Purchasers will receive registration rights for resale, adding future selling pressure.

Financial Impact

~$24M gross proceeds from 20.3M new shares, representing ~15.3% dilution on 133.2M shares outstanding. Combined with the $100M ATM and 58.9M S-3 resale shares, total potential dilution exceeds 100% of current float.

dilutionshare countcash balance

Risk Factors

  • Massive cumulative dilution from this placement, the $100M ATM, and the 58.9M-share S-3 resale registration
  • No active clinical programs; discontinued lead candidate Decoy20
  • Going-concern risk; company is evaluating strategic alternatives
  • Pivot to preclinical neurotechnology device is high-risk and early-stage
  • Potential Nasdaq listing compliance issues from excessive dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-042037
Document: form8-k.htm0001493152-26-042037
Document: 0001493152-26-042037-index-headers.html0001493152-26-042037
Document: 0001493152-26-042037-index.html0001493152-26-042037
Document: 0001493152-26-042037.txt0001493152-26-042037

Track record

20 reports on INDP

Performance horizon

3 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
  2. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  3. Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  4. Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
  5. Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
  6. Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
  8. Sep 9, 20269w ago 8-K Bearish 7/10 Viewing Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
  9. Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
  10. Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 10, 2026